Welgus Howard G. 4

What Happened
Howard G. Welgus, a director of Arcutis Biotherapeutics, sold 10,000 shares of ARQT stock in an open‑market transaction on February 2, 2026. The Form 4 reports a weighted average sale price of $25.05 per share for total proceeds of approximately $250,483. This transaction was a sale (not a purchase) and therefore is generally considered routine insider selling rather than a direct bullish signal.

Key Details

• Transaction date: February 2, 2026; Form 4 filed February 4, 2026 (appears timely).
• Reported weighted average price: $25.05; total proceeds: ~$250,483.
• Price range: individual trades executed between $24.61 and $25.60 (per filing footnote). Full breakdown by price available on request.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Footnote: The trades were effected under a 10b5‑1 trading plan adopted March 11, 2025, with a plan end date of May 29, 2026.

Context
Sales made under 10b5‑1 plans are pre‑arranged and aim to avoid concerns about trading on nonpublic information; they do not necessarily reflect a change in the insider’s view of the company. For retail investors, purchases by insiders tend to be more informative than routine sales, but tracking patterns of multiple insiders over time can provide additional context.